新型口服抗凝药利伐沙班在房颤患者中的应用效果分析  

Analysis of the application effect of a new oral anticoagulant(rivaroxaban)in patients with atrial fibrillation

作　　者：刘芳 夏镇萍 葛慧 LIU Fang;XIA Zhen-ping;GE Hui(Zhenjiang First People's Hospital,Zhenjiang 212002,China)

机构地区：[1]江苏省镇江市第一人民医院,212002

出　　处：《中国现代药物应用》2025年第5期67-70,共4页Chinese Journal of Modern Drug Application

摘　　要：目的分析新型口服抗凝药利伐沙班在心房颤动(房颤)患者中的应用效果。方法120例房颤患者,根据治疗方法不同分为对照组和研究组,每组60例。对照组采用华法林治疗,研究组采用新型口服抗凝药利伐沙班治疗。对比两组患者的治疗效果、凝血指标、血压水平及出血事件发生率。结果研究组患者治疗总有效率为98.33%,高于对照组的75.00%,差异具有统计学意义(P<0.05)。治疗后,研究组患者活化部分凝血活酶时间(30.11±1.28)s、凝血酶原时间(11.31±1.25)s长于对照组的(26.77±1.45)、(10.45±1.36)s,血小板计数(177.45±33.64)×10^(9)/L低于对照组的(200.64±31.24)×10^(9)/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者收缩压(128.64±7.61)mm Hg(1 mm Hg=0.133 kPa)、舒张压(83.12±3.16)mm Hg低于对照组的(141.87±7.03)、(91.54±3.64)mm Hg,差异具有统计学意义(P<0.05)。研究组出血事件发生率为1.67%(1/60),与对照组的3.33%(2/60)对比,差异无统计学意义(P>0.05)。结论房颤患者应用新型口服抗凝药利伐沙班治疗的临床效果显著,可切实改善病症,保证治疗安全性,值得推广。Objective To analyze the application effect of a new oral anticoagulant(rivaroxaban)in patients with atrial fibrillation.Methods 120 patients with atrial fibrillation were divided into a control group and a study group according to different treatment methods,with 60 cases in each group.The control group was treated with warfarin,and the study group was treated witha new oral anticoagulant(rivaroxaban).The therapeutic effect,coagulation index,blood pressure level and incidence of bleeding events were compared between the two groups.Results The total effective rate of the study group was 98.33%,which was higher than 75.00%of the control group,and the difference was statistically significant(P<0.05).After treatment,the activated partial thromboplastin time and prothrombin time of the study group were(30.11±1.28)and(11.31±1.25)s,which were longer than(26.77±1.45)and(10.45±1.36)s of the control group;the study group had a lower platelet count of(177.45±33.64)×10^(9)/L than(200.64±31.24)×10^(9)/L in the control group;the difference was statistically significant(P<0.05).After treatment,the systolic blood pressure in the study group was(128.64±7.61)mm Hg(1 mm Hg=0.133 kPa)and the diastolic blood pressure was(83.12±3.16)mm Hg,which were lower than(141.87±7.03)and(91.54±3.64)mm Hg in the control group,and the difference was statistically significant(P<0.05).The incidence of bleeding events in the study group was 1.67%(1/60),which had no statistical significance compared with 3.33%(2/60)in the control group(P>0.05).Conclusion During the treatment of patients with atrial fibrillation,the new oral anticoagulant(rivaroxaban)has a significant clinical effect,which can effectively improve the disease and ensure the safety of treatment,which is worth promoting.

关 键 词：心房颤动 利伐沙班 抗凝 凝血指标 华法林 疗效 安全性 

分 类 号：R54[医药卫生—心血管疾病]